On June 17, 2021 Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, reported that it has entered into a research collaboration agreement with Roche for the discovery of a novel Synthetic Biotic medicine for the treatment of inflammatory bowel disease (IBD)(Press release, Synlogic, JUN 17, 2021, View Source [SID1234584099]). Under the terms of the agreement, Synlogic and Roche will collaborate to develop a Synthetic Biotic medicine addressing an undisclosed novel target in IBD.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our mission is to develop Synthetic Biotic medicines that benefit patients in meaningful ways," said David Hava, Ph.D., Synlogic’s Chief Scientific Officer. "We are excited to expand our efforts in inflammation, working to address the unmet needs of patients with inflammatory bowel disease."

"We are excited to work with Synlogic and explore the potential of a new modality for the treatment of IBD," said James Sabry, Global Head, Roche Pharma Partnering. "Synlogic and Roche share a commitment to advancing innovative science and delivering transformative medicines to patients living with inflammatory disease."

At the conclusion of the research period, Roche will have the exclusive option to enter a licensing and collaboration agreement for further development and commercialization of the program.

Learn more about Synlogic’s programs and pipeline by visiting View Source